Eicosapentaenoic acid/docosahexaenoic acid - Pivotal Therapeutics

Drug Profile

Eicosapentaenoic acid/docosahexaenoic acid - Pivotal Therapeutics

Alternative Names: EPA/DHA - Pivotal; PVT-100; Vascazen

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pivotal Therapeutics
  • Class Antihyperlipidaemics; Docosahexaenoic acids; Eicosanoids; Omega 3 fatty acids; Unsaturated fatty acids
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Atherosclerosis
  • Clinical Phase Unknown Cardiovascular disorders

Most Recent Events

  • 05 Sep 2017 Phase-III development is ongoing in Atherosclerosis in France (NCT02582710)
  • 05 Jun 2015 Phase-II clinical trials in Atherosclerosis (stabilisation of plaque) in France (PO)
  • 01 Jun 2015 Pivotal Therapeutics initiates enrolment in a phase IIa trial for Atherosclerosis in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top